ChemRegen

San Diego, United States Founded: 2009 • Age: 17 yrs
Small molecule regenerative therapy for heart diseases and cancer

About ChemRegen

ChemRegen is a company based in San Diego (United States) founded in 2009.. ChemRegen offers products and services including PAWI-2, Cardiac Regeneration Technology, Breast Cancer Research, and Colorectal Cancer Therapy. ChemRegen operates in a competitive market with competitors including Tenaya Therapeutics, Orca Bio, Athira Pharma, Histogenics and Organogenesis, among others.

  • Headquarter San Diego, United States
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Chemregen, Inc
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Pharmaceuticals & Therapeutics
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Latest Funding Round
    $240.56 K (USD), Grant

    Jun 01, 2014

  • Investors
    HHS

    & 1 more

  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of ChemRegen

ChemRegen offers a comprehensive portfolio of products and services, including PAWI-2, Cardiac Regeneration Technology, Breast Cancer Research, and Colorectal Cancer Therapy. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Drug that inhibits pancreatic cancer stem cells and synergizes standard treatments.

Technology for developing treatments using stem cells for cardiac repair.

Research focused on regenerative approaches for breast cancer treatment.

Development of drugs targeting colorectal cancer through stem cell methods.

People of ChemRegen
Headcount 1-10
Employee Profiles 2
Board Members and Advisors 1
Employee Profiles
People
John R. Cashman
CEO

Unlock access to complete

Teams

Funding Insights of ChemRegen

  • Total Funding
  • Total Rounds 3
  • Last Round Grant — $240,555
  • First Round
  • Investors Count 2
Date Amount Transaction Name Valuation Lead Investors Investors
Jun, 2014 Amount Grant - ChemRegen Valuation

investors

HHS
Jul, 2011 Amount Grant - ChemRegen Valuation

investors

HHS
Mar, 2011 Amount Grant - ChemRegen Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in ChemRegen

ChemRegen has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and National Heart, Lung, and Blood Institute. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Public health and human services are overseen by HHS.
Founded Year Domain Location
Research on heart, lung, blood, and sleep disorders is conducted.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by ChemRegen

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - ChemRegen

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Chemregen Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of ChemRegen

ChemRegen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tenaya Therapeutics, Orca Bio, Athira Pharma, Histogenics and Organogenesis, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Regenerative and gene therapeutics for heart failure are developed.
domain founded_year HQ Location
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders
domain founded_year HQ Location
Neurodegenerative disease therapeutics, including for Alzheimer’s and Parkinson’s, are developed.
domain founded_year HQ Location
Restorative cell therapies for orthopedic diseases are developed.
domain founded_year HQ Location
Regenerative therapies for wound care are developed and commercialized.
domain founded_year HQ Location
Engineered cell and gene therapies are developed for multiple diseases.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Chemregen

Frequently Asked Questions about ChemRegen

When was ChemRegen founded?

ChemRegen was founded in 2009 and raised its 1st funding round 2 years after it was founded.

Where is ChemRegen located?

ChemRegen is headquartered in San Diego, United States. It is registered at San Diego, California, United States.

What does ChemRegen do?

ChemRegen is focussed on developing regenerative medicine for a range of diseases. Based on the stem cell biology, it has discovered small molecule regenerative medicine candidates which work in conjunction with the embryonic stem cells for the development of functionally active drugs. It currently has 2 major small molecule programs for heart disease and cancer. In partnership with the Human BioMolecular Research Institute Sanford-Burnham Medical Research Institute, it has developed a small molecule along ITD-1 which can be used to new heart cells from stem cells.

Who are the top competitors of ChemRegen?

ChemRegen's top competitors include Tenaya Therapeutics, Athira Pharma and Orca Bio.

What products or services does ChemRegen offer?

ChemRegen offers PAWI-2, Cardiac Regeneration Technology, Breast Cancer Research, and Colorectal Cancer Therapy.

Who are ChemRegen's investors?

ChemRegen has 2 investors. Key investors include HHS, and National Heart, Lung, and Blood Institute.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available